which was formed in1978 by Leonard Zacks

Recentpositive data from two trials, ACUITY and HORIZON, has helped boost Angiomaxsales in the past few quarters We think this trend will continue. We are alsolooking forward to the Cleviprex ramp and an interim analysis on phase IIIcandidate, Cangrelor in 2009. However, the recent deal to acquire Targanta (NASDAQ: TARG) and its phase IIIcandidate (oritavancin) is a distraction, in our opinion We do not seeoritavancin on the market until 2012 at best As such, our rating is now Hold. Petroleum Dev'pment a Real ValueWe are maintaining our Buy recommendation, but lowering our price objective andestimates for Petroleum Development (NASDAQ: PETD) ahead of the company'sfourth-quarter results. The negative revisions primarily reflect our new (lower)commodity-price deck. Our new fourth-quarter 2008 and full-year 2009 EPS estimates are $0.66 and$3.54, down from $1.46 and $5.10, respectively.

Despite recent turmoil, the PETDstory remains intact, with low risk drilling in its three Colorado operatingareas along with accretive acquisitions providing the fuel for double-digitproduction growth through 2010. We project that the company can sustainproduction growth in 2009 even while reducing capital outlays WellPoint a Buy Pre-EarningsWellPoint, Inc. (NYSE: WLP) is the largest publicly traded commercial healthbenefits company, in terms of membership in the US. On January 12, 2009, WLPannounced that The Centers for Medicare and Medicaid Services (CMS) hadsuspended the company from enrolling new patients in the health insuranceMedicare Advantage plan and the prescription drug benefit, Medicare Part D dueto a "sharp" increase in consumer complaints. We believe the action by CMS is reversible and highlights operational issuesthat can be addressed by management in the short term. Want more from Zacks Equity Research Subscribe to the free Profit from the Prosnewsletter: About Zacks Equity ResearchZacks Equity Research provides the best of quantitative and qualitative analysisto help investors know what stocks to buy and which to sell for the long-term. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latestanalysis from Zacks Equity Research.

Subscribe to this free newsletter today: ZacksZacks is a property of Zacks Investment Research, Inc., which was formed in1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patternsin stock market data that would lead to superior investment results. The best way to unlock the profitable stock recommendations and marketinsights of Zacks Investment Research is through our free daily emailnewsletter; Profit from the Pros. In short, it's your steady flow of Profitableideas GUARANTEED to be worth your time! Register for your free subscription toProfit from the Pros at Visit http:// for information about the performancenumbers displayed in this press release. Disclaimer: Past performance does not guarantee future results. Investors shouldalways research companies and securities before making any investments.